Lapatinib
Specifications
231277-92-2CAS Number
878-720-7EC Number
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amineIUPAC Name
C29H26ClFN4O4SChemical Formula
581.1 g/molMolecular Weight
Lapatinib; 231277-92-2; GW572016; GW 572016; GSK 572016; GW-572016; DTXSID7046675; n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine; GSK572016; GSK-572016; 0VUA21238F; N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine; GW-572016X; DTXCID5026675; CHEBI:49603; GW2016; 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-; N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine; 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-; lapatinibum; N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-methanesulfonylethyl)amino)methyl)furan-2-yl)quinazolin-4-amine; RefChem:798502; L01XE07; GW 2016; GW-282974X; 878-720-7; N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl)-2-furyl)-4-quinazolinamine; NSC727989; Tykerb; Lapatinib [INN]; Lapatinib free base; Lapatinib (free base); Lapatanib; Lapatinib base; C29H26ClFN4O4S; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; Lapatinib (INN); MFCD09264194; FMM; N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine; 1210608-87-9; N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; CHEMBL554; Lapatinib (GW572016); NSC745750; s2111; NCGC00167507-01; GW 282974X; GW-2016; 913989-15-8; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; CAS-231277-92-2; Lapatinib [INN:BAN]; 231277-92-2 (free base); L0360; UNII-0VUA21238F; Lapatinib?; Tykerb;; HSDB 8209; 1xkk; N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; Lapatinib ditosylate?; Lapatinib (Standard); Lapatinib, Free base; nchembio866-comp20; Kinome_3684; Kinome_3685; LAPATINIB [MI]; LAPATINIB [VANDF]; LAPATINIB [WHO-DD]; SCHEMBL8100; LAPATINIB [EMA EPAR]; BDBM5445; cid_208908; GTPL5692; orb1225581; orb1310962; orb3141254; SCHEMBL29351024; SCHEMBL29464189; BDBM32368; EX-A402; BCFGMOOMADDAQU-UHFFFAOYSA-N; GLXC-06463; HMS2089H10; HMS3244N06; HMS3244N10; HMS3244N14; HMS3744K11; HMS5080G12; Tykerb (TN) (Glaxo Smith Kline); Lapatinib base - Bio-X trade mark; LAPATINIB (GW-572016); Tox21_112505; EBC-00694; HY-50898R; NSC800780; AKOS005145766; Tox21_112505_1; AC-1314; CCG-270133; DB01259; FC12433; NSC-745750; NSC-800780; SB16918; SDCCGSBI-0634417.P003; NCGC00167507-02; NCGC00167507-03; NCGC00167507-04; NCGC00167507-09; NCGC00167507-17; NCGC00167507-18; AS-14065; BC164610; BP-43661; HY-50898; N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; NS00003012; SW199101-5; D08108; EN300-117254; AB01273965-01; AB01273965-02; AB01273965-03; AB01273965_04; AB01273965_05; Q420323; SR-05000001472-1; BRD-K19687926-001-01-7; BRD-K19687926-001-04-1; BRD-K19687926-001-10-8; BRD-K19687926-379-02-5; BRD-K19687926-379-07-4; 1092929-10-6; LAPATINIB FREE BASETYKERBLAPATINIBGW 572016N-(3-CHLORO-4-{[(3-FLUOROPHENYL)METHYL]OXY}PHENYL)-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURANYL]-4-QUINAZOLINAMINE; N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine; N-{3-chloro-4-[(3-fluoro-benzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; N-{3-Chloro-4[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamineSynonyms
Products Containing Lapatinib
Companies Selling Lapatinib
JM
Jiangsu Magic Biotechnology Co., LtdChinaSI
Sinoway Industrial Co.Ltd.ChinaHH
HANGZHOU HONGQIN PHARMTECH CO.,LTDChinaSS
Shanghai Sunway Pharmaceutical Technoiogy Co.,LtdChinaBE
BEIJING EARLYBIRD INDUSTRY DEVELOPMENT CO.,LTD.China
NE
Novartis Europharm LimitedSpain
AC
AFINE CHEMICALS LIMITED